Table 1 The different targets between anlotinib and other RTK inhibitors
From: Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
| Â | VEGFR | PDGFR | FGFR | Others | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
1 | 2 | 3 | α | β | 1 | 2 | 3 | 4 | ||
Sorafenib | + | + | + | – | + | – | – | – | – | RET (+), c-KIT(+), FLT3(+) |
Sunitinib | + | + | + | + | + | – | – | – | – | FLT3(+), c-KIT(+), RET(+), CSF1R(+) |
Axitinib | + | + | + | – | – | – | – | – | – | – |
Vatalanib | + | + | + | – | + | – | – | – | – | c-KIT(+) |
Nintedanib | + | + | + | + | + | + | + | + | – | FLT3(+), Src(+) |
Pazopanib | + | + | + | + | + | + | – | – | – | c-KIT(+) |
Anlotinib | + | + | + | + | + | + | + | + | + | c-KIT(+) |